Ascendis Pharma A/S (NASDAQ:ASND) PT Raised to $160.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by investment analysts at TD Cowen from $157.00 to $160.00 in a report released on Monday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. TD Cowen’s target price would indicate a potential upside of 23.96% from the stock’s current price.

Several other analysts have also commented on ASND. Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, September 16th. Bank of America boosted their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Wells Fargo & Company increased their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. The Goldman Sachs Group boosted their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Finally, Jefferies Financial Group lifted their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $195.23.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $129.07 on Monday. The stock’s 50-day moving average is $135.54 and its 200 day moving average is $134.88. The company has a market cap of $7.52 billion, a PE ratio of -13.22 and a beta of 0.64. Ascendis Pharma A/S has a 1 year low of $85.29 and a 1 year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. Analysts expect that Ascendis Pharma A/S will post -7.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Signaturefd LLC raised its holdings in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 80 shares during the last quarter. Diversified Trust Co purchased a new stake in Ascendis Pharma A/S during the 3rd quarter valued at $6,260,000. Handelsbanken Fonder AB lifted its holdings in shares of Ascendis Pharma A/S by 31.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 17,667 shares of the biotechnology company’s stock valued at $2,638,000 after buying an additional 4,200 shares during the period. Quarry LP boosted its stake in shares of Ascendis Pharma A/S by 257.1% in the 2nd quarter. Quarry LP now owns 2,500 shares of the biotechnology company’s stock worth $341,000 after buying an additional 1,800 shares during the last quarter. Finally, Algert Global LLC grew its holdings in shares of Ascendis Pharma A/S by 54.6% in the second quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company’s stock worth $297,000 after acquiring an additional 770 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.